Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Gastrointestinal 1

Conditions

Breast Neoplasms 8Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Cardiotoxicity 3Triple Negative Breast Neoplasms 2Neoplasms 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Leukemia 2Heart Failure 2Glioblastoma 2Endometrial Neoplasms 2Endometrial Hyperplasia 2Waldenstrom Macroglobulinemia 1Rectal Neoplasms 1Precancerous Conditions 1Polycystic Ovary Syndrome 1Overall Survival 1Neoplastic Cells, Circulating 1Nasopharyngeal Carcinoma 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1

Interventions

Fluorouracil 87Leucovorin 78Oxaliplatin 77Irinotecan 76Bevacizumab 50Cetuximab 42Capecitabine 42Panitumumab 17Folfox protocol 16Floxuridine 11Chemotherapy, Adjuvant 11regorafenib 10IFL protocol 10Nivolumab 9Drug Therapy 9trifluridine tipiracil drug combination 8Surgical Procedures, Operative 8Neoadjuvant Therapy 8sargramostim 7pembrolizumab 7XELOX 7Specimen Handling 7Biopsy 7Trastuzumab 6Radiotherapy 6Magnetic Resonance Spectroscopy 6HMPL-013 6tislelizumab 5encorafenib 5Trifluridine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Colonic Neoplasms × Atorvastatin × Clear all
NCT00335504 2017-02-15

Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia

National Cancer Institute (NCI)

Phase 2 Completed
85 enrolled 10 charts
GastrointestinalOther neoplasm

Colonic Neoplasms, Precancerous Conditions, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡